Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women
- 9 April 2018
- journal article
- research article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 19 (3) , 94-100
Abstract
(2018). Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women. HIV Clinical Trials: Vol. 19, No. 3, pp. 94-100.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Merck (MISP 38735)
This publication has 17 references indexed in Scilit:
- Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and EfficacyClinical Infectious Diseases, 2015
- Raltegravir Pharmacokinetics in Neonates Following Maternal DosingJAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Short Communication: Use of Raltegravir in Late-Presenting HIV-Infected Pregnant WomenAIDS Research and Human Retroviruses, 2013
- Rapid Decline in HIV Viral Load When Introducing Raltegravir-Containing Antiretroviral Treatment Late in PregnancyAIDS Patient Care and STDs, 2012
- Meta-Analysis of the Safety, Tolerability, and Efficacy of Lopinavir/Ritonavir-Containing Antiretroviral Therapy in HIV-1–Infected WomenHIV Research & Clinical Practice, 2012
- Raltegravir in the prevention of mother-to-child transmission of HIV-1AIDS, 2012
- Barriers to Prevention of HIV Type 1 Mother-to-Child-Transmission in Bahia, BrazilAIDS Research and Human Retroviruses, 2012
- Factors associated with viral load suppression in HIV-infected pregnant women in Rio de Janeiro, BrazilInternational Journal of STD & AIDS, 2012
- A Meta-analysis to Assess the FDA DAVP’s TLOVR Algorithm in HIV SubmissionsDrug Information Journal, 2011
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialThe Lancet, 2009